Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Sees Opportunity In Big Pharma’s Move To Specialty Products

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO McKinnell says the move into specialty markets by competitors enables Pfizer to take advantage of openings in the primary care arena.

You may also be interested in...



Pfizer Adds To Primary Care Pipeline Through Bayer Deal

DGAT-1 inhibitor licensing agreement gives Pfizer a novel Phase I obesity and diabetes product.

Pfizer Adds To Primary Care Pipeline Through Bayer Deal

DGAT-1 inhibitor licensing agreement gives Pfizer a novel Phase I obesity and diabetes product.

Wyeth Sales Force Reductions Have Not Impacted Market Share, Exec Maintains

Wyeth's sales force re-organization has resulted in the elimination of 800 reps over the last seven months.

Topics

UsernamePublicRestriction

Register

PS045148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel